Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SpayVac for Wildlife
Madison, Wisconsin, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
SpayVac’s single-dose vaccine provides long-lasting (4–10 years) immunocontraception, proven effective in various species (horses, deer, seals) with proof-of-concept and ongoing studies in aquaculture and elephants
- Therapeutic areas
- OtherEndocrinology
- Modalities
- Liposome-based vaccineVaccineLipid nanoparticle delivery therapy
- Industry
- Veterinary
02
Partnerships
BioVaxys Technology Corp. (platform licensor/technology partner; vaccine development & trials)U.S. Bureau of Land Management (trial and regulatory partner for horse program)Elephant and Wildlife Clinic, Faculty of Veterinary Medicine (field trial partner for elephants)Aquaculture sector trial partners (unnamed)
Beyond the preview
Go deeper on SpayVac for Wildlife.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SpayVac for Wildlife.